Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis

Jensen, Klaus Gjervig; Correll, Christoph U.; Rudå, Ditte; Klauber, Dea Gowers; Stentebjerg-Olesen, Marie; Fagerlund, Birgitte; Jepsen, Jens Richardt Møllegaard; Fink-Jensen, Anders; Pagsberg, Anne Katrine

doi:10.4088/jcp.15m10479

Cited by 37 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Age, gender, race, parental education, and lifetime nicotine use were considered as potential covariates based on group differences in our sample and prior research. 46 Age, gender, and parental education were significantly associated with at least one of the metabolic variables and were included as covariates. Additionally, prior clinically significant second-generation antipsychotic use (i.e., ≥3 months) was examined as a covariate because of the known association with weight gain.…”

Section: Discussionmentioning

confidence: 99%

“…Logistic regression models were used to examine group differences on the binary metabolic variables. Age, gender, race, parental education, and lifetime nicotine use were considered as potential covariates based on group differences in our sample and prior research . Age, gender, and parental education were significantly associated with at least one of the metabolic variables and were included as covariates.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Similar findings were found in youth through the recent Tolerability and Efficacy of Antipsychotics (TEA) trial. Drug-naïve first-episode psychosis patients ages 12–17 years had higher waist circumference, total cholesterol, LDL, and non-HDL levels compared to controls (Jensen et al, 2017 ). These suggestions have been challenged in meta-analyses that exclude patients with affective psychosis (which could lead to confounding changes in dietary or exercise habits).…”

Section: Contemporary Evidence Of Intrinsic Metabolic Risk In Schizopmentioning

confidence: 99%

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia

et al. 2017

View full text Add to dashboard Cite

For decades, there have been observations demonstrating significant metabolic disturbances in people with schizophrenia including clinically relevant weight gain, hypertension, and disturbances in glucose and lipid homeostasis. Many of these findings pre-date the use of antipsychotic drugs (APDs) which on their own are also strongly associated with metabolic side effects. The combination of APD-induced metabolic changes and common adverse environmental factors associated with schizophrenia have made it difficult to determine the specific contributions of each to the overall metabolic picture. Data from drug-naïve patients, both from the pre-APD era and more recently, suggest that there may be an intrinsic metabolic risk associated with schizophrenia. Nevertheless, these findings remain controversial due to significant clinical variability in both psychiatric and metabolic symptoms throughout patients' disease courses. Here, we provide an extensive review of classic and more recent literature describing the metabolic phenotype associated with schizophrenia. We also suggest potential mechanistic links between signaling pathways associated with schizophrenia and metabolic dysfunction. We propose that, beyond its symptomatology in the central nervous system, schizophrenia is also characterized by pathophysiology in other organ systems directly related to metabolic control.

show abstract

“…36 The study on early-onset psychosis conducted on teenage population by Jensen et al also indicated that elevated metabolic risk with dyslipidemia may be present even prior to pharmacotherapy. 37 There are some limitations in this study that need to be discussed. The sample of our study was limited to 20 PWS patients and 18 DGS patients due to the rarity of the syndromes as well as exclusion of patients with lower levels of intellectual functioning.…”

Section: Discussionmentioning

confidence: 94%

<p>Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation</p>

Krefft

Frydecka

Śmigiel

et al. 2020

NDT

View full text Add to dashboard Cite

Purpose: The purpose of our study was to compare the metabolic parameters in two genetic syndromes with a proven high risk of developing psychiatric comorbidities. These comorbidities, especially mood and psychotic disorders, may be associated with a risk of obesity, type 2 diabetes and other components of metabolic syndrome regardless of antipsychotic treatment. Patients and Methods: Two groups of children diagnosed with Prader -Willi syndrome (PWS) (n = 20) and DiGeorge syndrome (DGS) (n = 18), aged 7-18 years, were enrolled. Behavioral symptoms and co-occurring psychopathological symptoms were assessed using the Child Behavior Checklist (CBCL). The levels of following biochemical parameters were measured: glucose, insulin, high-sensitivity C-reactive protein, total cholesterol, low-and high-density lipoproteins (LDL and HDL), triglycerides and non-HDL cholesterol. Additionally, the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was calculated. Results: There were significantly higher levels of insulin and non-HDL in patients with PWS compared to those with DGS. The scores of four CBCL subscales (social problems, thought problems, delinquent behavior and aggressive behavior) were significantly higher in PWS patients. Higher scores of the CBCL-thought problems were associated with significantly higher levels of insulin as well as HOMA-IR. Conclusion: Patients with PWS seem to be more prone to develop subclinical metabolic dysregulation, in terms of elevated non-HDL levels and insulin levels, compared to DGS patients. Altered insulin sensitivity, present in both groups, even though it is not a specific risk factor, might be related to thought problems associated with psychosis.

show abstract

Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis

Abstract: ClinicalTrials.gov identifier: NCT01119014; European Clinical Trials Database (EudraCT): 2009-016715-38.

Cited by 37 publications

References 0 publications

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia

<p>Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation</p>

Contact Info

Product

Resources

About

Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis

Abstract: ClinicalTrials.gov identifier: NCT01119014; European Clinical Trials Database (EudraCT): 2009-016715-38​​​.

Cited by 37 publications

References 0 publications

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder

Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia

<p>Metabolic Parameters in Patients with Prader-Willi Syndrome and DiGeorge Syndrome with Respect to Psychopathological Manifestation</p>

Contact Info

Product

Resources

About

Abstract: ClinicalTrials.gov identifier: NCT01119014; European Clinical Trials Database (EudraCT): 2009-016715-38.